{
    "clinical_study": {
        "@rank": "35231", 
        "arm_group": [
            {
                "arm_group_label": "Low dose of blueberry dry powder", 
                "arm_group_type": "Experimental", 
                "description": "0.5 g blueberry dry powder, twice a day for 12 weeks"
            }, 
            {
                "arm_group_label": "High dose of blueberry dry powder", 
                "arm_group_type": "Experimental", 
                "description": "5.0 g blueberry dry powder, twice a day for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the present study is to evaluate the effect of blueberry dry powder on\n      glycemic status (fasting plasma glucose, 2h glucose concentration after the oral glucose\n      tolerance test (OGTT), or HbA1c) in subjects with prediabetes."
        }, 
        "brief_title": "Effects of Blueberry Dry Powder on Glycemic Status in Subjects With Prediabetes", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prediabetes", 
        "condition_browse": {
            "mesh_term": [
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Fasting plasma glucose 110-125 mg/dL\n\n        Exclusion Criteria:\n\n          -  Taking anti-diabetic drugs\n\n          -  Taking drugs or functional food that may affect blood glucose level\n\n          -  Fruit allergy\n\n          -  Pregnant or nursing a child\n\n          -  Participation in any clinical trial within 90 days of the commencement of the trial\n\n          -  Renal or hepatic dysfunction\n\n          -  Heart disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02023320", 
            "org_study_id": "eki-842"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low dose of blueberry dry powder", 
                "intervention_name": "Low dose of blueberry dry powder", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "High dose of blueberry dry powder", 
                "intervention_name": "High dose of blueberry dry powder", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 23, 2013", 
        "location": {
            "contact": {
                "email": "fumiko@hiroshima-u.ac.jp", 
                "last_name": "Fumiko Higashikawa, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Hiroshima", 
                    "country": "Japan", 
                    "zip": "734-8551"
                }, 
                "name": "Hiroshima University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of Blueberry Dry Powder on Prediabetes", 
        "overall_contact": {
            "email": "fumiko@hiroshima-u.ac.jp", 
            "last_name": "Fumiko Higashikawa, PhD", 
            "phone": "+81-82-257-1533"
        }, 
        "overall_official": {
            "affiliation": "Hiroshima University", 
            "last_name": "Fumiko Higashikawa, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in fasting plasma glucose from baseline", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks (Overall 12 weeks)"
            }, 
            {
                "measure": "Change in 2h glucose concentration after the oral glucose tolerance test (OGTT) from baseline", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0 and 12"
            }, 
            {
                "measure": "Change in HbA1c from baseline", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0 and 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02023320"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hiroshima University", 
            "investigator_full_name": "Fumiko Higashikawa", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in glycoalbumin from baseline", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks (Overall 12 weeks)"
            }, 
            {
                "measure": "Change in fasting insulin from baseline", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0 and 12"
            }, 
            {
                "description": "HOMA-R is calculated as fasting insulin (mU/mL) x fasting glucose (mg/dL) / 405", 
                "measure": "Change in homeostasis model assessment-insulin resistance (HOMA-R) from baseline", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0 and 12"
            }, 
            {
                "measure": "Change in serum C-peptide from baseline", 
                "safety_issue": "No", 
                "time_frame": "Weeks 0 and 12"
            }
        ], 
        "source": "Hiroshima University", 
        "sponsors": {
            "collaborator": {
                "agency": "Agricultural Producers' Cooperative Corporation Shinpo-en", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Hiroshima University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}